Search company, investor...

Sirius Genomics

Founded Year



Grant | Alive

Total Raised


About Sirius Genomics

Developer of diagnostics and pharmacogenetic tests for critical care medicine. The company develops DNA-based diagnostic (Dx) and pharmacogenetic (PGx) tests for critical care. The main product focus is concentrated on the development of Dx and PGx tests for sepsis, a systemic blood infection. [Keywords: personalized medicine]

Headquarters Location

1125 Howe Street, Suite 603

Vancouver, British Columbia, V6Z 2K8,



Missing: Sirius Genomics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Sirius Genomics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Sirius Genomics Frequently Asked Questions (FAQ)

  • When was Sirius Genomics founded?

    Sirius Genomics was founded in 2001.

  • Where is Sirius Genomics's headquarters?

    Sirius Genomics's headquarters is located at 1125 Howe Street, Suite 603, Vancouver.

  • What is Sirius Genomics's latest funding round?

    Sirius Genomics's latest funding round is Grant.

  • How much did Sirius Genomics raise?

    Sirius Genomics raised a total of $5.1M.

  • Who are the investors of Sirius Genomics?

    Investors of Sirius Genomics include National Research Council Canada.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.